Commentary|Articles|February 19, 2025

Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

The 2025 Genitourinary (GU) Cancers Symposium concluded on Saturday, February 15, 2025, after 3 days of presentations showcasing emerging data across the fields of urothelial cancer, prostate cancer, and renal cell carcinoma (RCC). From practice-changing research to promising therapies in development, the following GU cancer experts shared their most notable takeaways in interviews with OncLive^®:

Related to this article

RCC | Image Credit: © Ashling Wahner & MJH Life Sciences Using AI

July 15th, 2026

Adjuvant Penpulimab Improves DFS in Very High-Risk Clear Cell RCC

Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.

NSCLC | Image Credit: Ashling Wahner & MJH Life Sciences Using AI

July 21st, 2026

Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC

An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.

Cancer research | Image Credit: © catalin - stock.adobe.com

July 21st, 2026

Study Finds Bringing Clinical Trials Closer to Patients Expands Access to Research

Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.

Indolent non-Hodgkin lymphoma | Image Credit: © Nicat - stock.adobe.com

July 21st, 2026

EO2463-Induced CD8 T-Cell Expansion Correlates With Survival Outcomes in Indolent NHL

Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.

Alpha DaRT Plus Pembrolizumab in Elderly Recurrent or Metastatic HNSCC: ©G.Go - stock.adobe.com

July 21st, 2026

Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC

Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.

July 21st, 2026

Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL

High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.

Melanoma | Image Credit: © Maris - stock.adobe.com

July 20th, 2026

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

Head and neck cancer | Image Credit: © Creative Station - stock.adobe.com

July 20th, 2026

Roswell Park to Spotlight Advances in AI, Immunotherapy and Surgery at International Head/Neck Cancer Meeting

Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.